Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label study of chlorbenzoxamic acid meglumine soft capsules in adult transthyretin amyloid polyneuropathy
CTR20251216Phase 4Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafamidis meglumine in familial amyloid polyneuropathy (FAP), sponsored by Qilu Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
tafamidis meglumine
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on CTR20251216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251216.